Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice

Abstract Hydroxychloroquine has recently received attention as a treatment for COVID-19. However, it may prolong the QTc interval. Furthermore, when hydroxychloroquine is administered concomitantly with other drugs, it can exacerbate the risk of QT prolongation. Nevertheless, the risk of QT prolonga...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Byung Jin Choi, Yeryung Koo, Tae Young Kim, Wou Young Chung, Yun Jung Jung, Ji Eun Park, Hong-Seok Lim, Bumhee Park, Dukyong Yoon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5e76cb6ce35c44c5b3b7684233b37918
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e76cb6ce35c44c5b3b7684233b37918
record_format	dspace
spelling	oai:doaj.org-article:5e76cb6ce35c44c5b3b7684233b379182021-12-02T17:04:05ZRisk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice10.1038/s41598-021-86321-z2045-2322https://doaj.org/article/5e76cb6ce35c44c5b3b7684233b379182021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86321-zhttps://doaj.org/toc/2045-2322Abstract Hydroxychloroquine has recently received attention as a treatment for COVID-19. However, it may prolong the QTc interval. Furthermore, when hydroxychloroquine is administered concomitantly with other drugs, it can exacerbate the risk of QT prolongation. Nevertheless, the risk of QT prolongation due to drug-drug interactions (DDIs) between hydroxychloroquine and concomitant medications has not yet been identified. To evaluate the risk of QT prolongation due to DDIs between hydroxychloroquine and 118 concurrent drugs frequently used in real-world practice, we analyzed the electrocardiogram results obtained for 447,632 patients and their relevant electronic health records in a tertiary teaching hospital in Korea from 1996 to 2018. We repeated the case–control analysis for each drug. In each analysis, we performed multiple logistic regression and calculated the odds ratio (OR) for each target drug, hydroxychloroquine, and the interaction terms between those two drugs. The DDIs were observed in 12 drugs (trimebutine, tacrolimus, tramadol, rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, piperacillin/tazobactam, isoniazid, clarithromycin, and furosemide), all with a p value of < 0.05 (OR 1.70–17.85). In conclusion, we found 12 drugs that showed DDIs with hydroxychloroquine in the direction of increasing QT prolongation.Byung Jin ChoiYeryung KooTae Young KimWou Young ChungYun Jung JungJi Eun ParkHong-Seok LimBumhee ParkDukyong YoonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Byung Jin Choi Yeryung Koo Tae Young Kim Wou Young Chung Yun Jung Jung Ji Eun Park Hong-Seok Lim Bumhee Park Dukyong Yoon Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
description	Abstract Hydroxychloroquine has recently received attention as a treatment for COVID-19. However, it may prolong the QTc interval. Furthermore, when hydroxychloroquine is administered concomitantly with other drugs, it can exacerbate the risk of QT prolongation. Nevertheless, the risk of QT prolongation due to drug-drug interactions (DDIs) between hydroxychloroquine and concomitant medications has not yet been identified. To evaluate the risk of QT prolongation due to DDIs between hydroxychloroquine and 118 concurrent drugs frequently used in real-world practice, we analyzed the electrocardiogram results obtained for 447,632 patients and their relevant electronic health records in a tertiary teaching hospital in Korea from 1996 to 2018. We repeated the case–control analysis for each drug. In each analysis, we performed multiple logistic regression and calculated the odds ratio (OR) for each target drug, hydroxychloroquine, and the interaction terms between those two drugs. The DDIs were observed in 12 drugs (trimebutine, tacrolimus, tramadol, rosuvastatin, cyclosporin, sulfasalazine, rofecoxib, diltiazem, piperacillin/tazobactam, isoniazid, clarithromycin, and furosemide), all with a p value of < 0.05 (OR 1.70–17.85). In conclusion, we found 12 drugs that showed DDIs with hydroxychloroquine in the direction of increasing QT prolongation.
format	article
author	Byung Jin Choi Yeryung Koo Tae Young Kim Wou Young Chung Yun Jung Jung Ji Eun Park Hong-Seok Lim Bumhee Park Dukyong Yoon
author_facet	Byung Jin Choi Yeryung Koo Tae Young Kim Wou Young Chung Yun Jung Jung Ji Eun Park Hong-Seok Lim Bumhee Park Dukyong Yoon
author_sort	Byung Jin Choi
title	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
title_short	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
title_full	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
title_fullStr	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
title_full_unstemmed	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
title_sort	risk of qt prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5e76cb6ce35c44c5b3b7684233b37918
work_keys_str_mv	AT byungjinchoi riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT yeryungkoo riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT taeyoungkim riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT wouyoungchung riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT yunjungjung riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT jieunpark riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT hongseoklim riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT bumheepark riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice AT dukyongyoon riskofqtprolongationthroughdruginteractionsbetweenhydroxychloroquineandconcomitantdrugsprescribedinrealworldpractice
_version_	1718381850176520192

Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice

Ejemplares similares